Jaguar Health, Inc.
JAGX · XNASCIK 1585608fmd_10B05PE2KBV4Y4A8X4WSS3K1A9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Jun 30, 2026, 50 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 4 | 4 | 6 | 9 | 4 | 12 | 10 | 12 | 12 |
| Cost of revenue | 0 | 1 | 3 | 4 | 3 | 2 | 2 | 2 | 2 | 4 |
| Gross profit | 0 | 3 | 2 | 2 | 6 | 2 | 10 | 8 | 10 | 8 |
| Research and development | 7 | 4 | 5 | 6 | 6 | 15 | 18 | 19 | 17 | 25 |
| Selling, general and administrative | 6 | 14 | 22 | 20 | 21 | 26 | 27 | 23 | 24 | 28 |
| Total operating expenses | 14 | 39 | 35 | – | – | – | – | – | – | – |
| Operating income | (14) | (34) | (31) | (29) | (27) | (41) | (34) | (34) | (31) | (46) |
| Interest expense | 1 | 1 | 3 | 6 | 3 | 8 | 13 | 6 | 0 | 0 |
| Other non-operating income (expense) | (0) | 0 | 0 | 0 | 0 | (1) | 1 | 0 | 0 | 0 |
| Income before taxes | (15) | (35) | (32) | (39) | (34) | (53) | (48) | (42) | (39) | (54) |
| Income tax expense | – | (13) | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (22) | – | (39) | (34) | (53) | (48) | (42) | (39) | (54) |
| Net income | (15) | (22) | (32) | (39) | (34) | (0) | (0) | (0) | (38) | (54) |
| Net income to common shareholders | (15) | (22) | (32) | – | (39) | (53) | (47) | (41) | (38) | (54) |